<div id="readability-page-1"><p>Thurston Springer Miller Herd &amp; Titak Inc. grew its stake in shares of  Johnson &amp; Johnson (NYSE:JNJ - Free Report) by 23.2% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 28,009 shares of the company's stock after buying an additional 5,277 shares during the period. Thurston Springer Miller Herd &amp; Titak Inc.'s holdings in Johnson &amp; Johnson were worth $4,279,000 as of its most recent filing with the SEC.</p><div><p><span></span><span>Get <strong>Johnson &amp; Johnson</strong> alerts:</span></p></div><ul><li>As the Market Rotates, This Healthcare ETF Is Leading the Way</li></ul><p>A number of other large investors have also made changes to their positions in JNJ. Nuveen LLC acquired a new position in  Johnson &amp; Johnson in the first quarter worth about $1,369,188,000.  GAMMA Investing LLC raised its position in  Johnson &amp; Johnson by 24,450.4% in the first quarter. GAMMA Investing LLC now owns 7,215,367 shares of the company's stock worth $1,196,596,000 after purchasing an additional 7,185,977 shares in the last quarter.  Bank of New York Mellon Corp raised its position in  Johnson &amp; Johnson by 26.4% in the first quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock worth $3,844,580,000 after purchasing an additional 4,842,582 shares in the last quarter.  Pacer Advisors Inc. raised its position in  Johnson &amp; Johnson by 1,382.0% in the first quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company's stock worth $502,509,000 after purchasing an additional 2,825,626 shares in the last quarter.  Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in  Johnson &amp; Johnson in the fourth quarter worth about $349,206,000. Institutional investors and hedge funds own  69.55% of the company's stock. </p><h2>Insider Transactions at Johnson &amp; Johnson</h2><p>In other Johnson &amp; Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the firm's stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Insiders own  0.16% of the company's stock. </p><h2>Wall Street Analyst Weigh In</h2><ul><li>JNJ Stock Surge Signals Confidence in New Growth Path</li></ul><p>Several research analysts recently issued reports on JNJ shares. Piper Sandler  reissued an &#34;overweight&#34; rating on shares of Johnson &amp; Johnson in a research report on Thursday, July 17th. Guggenheim  reaffirmed a &#34;neutral&#34; rating and set a $167.00 price objective (up from $164.00) on shares of Johnson &amp; Johnson in a research note on Thursday, July 17th. Citigroup upped their price objective on shares of Johnson &amp; Johnson from $185.00 to $200.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, August 21st. Morgan Stanley upped their price objective on shares of Johnson &amp; Johnson from $171.00 to $176.00 and gave the stock an &#34;equal weight&#34; rating in a research note on Thursday, July 17th. Finally, Erste Group Bank raised shares of Johnson &amp; Johnson from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Wednesday, July 23rd. Two research analysts have rated the stock with a Strong Buy rating, nine have issued  a Buy rating and nine have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock  has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $176.29.</p><p><b>Read Our Latest Stock Analysis on JNJ</b></p><h2>Johnson &amp; Johnson Price Performance</h2><ul><li>3 Big Dividend Plays With Strong Earnings to Back Them</li></ul><p>JNJ opened at $178.10 on Friday. Johnson &amp; Johnson has a one year low of $140.68 and a one year high of $181.16. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The company's 50 day simple moving average is $170.81 and its 200-day simple moving average is $161.29. The stock has a market capitalization of $428.93 billion, a P/E ratio of 19.05, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40. </p><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson &amp; Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. During the same period in the prior year, the firm earned $2.82 earnings per share. Johnson &amp; Johnson's revenue was up 5.8% compared to the same quarter last year.  Johnson &amp; Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Sell-side analysts anticipate that  Johnson &amp; Johnson will post 10.58 earnings per share for the current fiscal year. </p><h2>Johnson &amp; Johnson Dividend Announcement</h2><p>The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were paid a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. Johnson &amp; Johnson's dividend payout ratio (DPR) is presently 55.61%. </p><h2>About Johnson &amp; Johnson</h2> (Free Report)<p>Johnson &amp; Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Johnson &amp; Johnson</li><li>Trading Stocks: RSI and Why it's Useful</li><li>Ride the Luxury Retail Wave with These 3 High-End Brand Stocks</li><li>Dividend Capture Strategy: What You Need to Know</li><li>Wall Street Quietly Bets Big on These Chinese Tech Giants</li><li>3 Tickers Leading a Meme Stock Revival</li><li>Meta's $600B U.S. Investment: Bearish or Bullish for Shares? </li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Thurston Springer Miller Herd & Titak Inc. increased its stake in Johnson & Johnson (NYSE: JNJ) by 23.2% in Q2, owning 28,009 shares valued at $4.28 million. Other investors, including Nuveen LLC and GAMMA Investing LLC, also adjusted their positions significantly. Insider Jennifer L. Taubert sold 56,471 shares, reducing her ownership by 24.08%. Analysts maintain a "Moderate Buy" consensus on JNJ, with a target price of $176.29. JNJ's stock opened at $178.10, with a market cap of $428.93 billion and a P/E ratio of 19.05.</p>

Thurston Springer Miller Herd & Titak Inc. Has $4.28 Million Position in Johnson & Johnson $JNJ